Alexis, Andrew
de Bruin-Weller, Marjolein
Weidinger, Stephan
Soong, Weily
Barbarot, Sebastien
Ionita, Ileana
Zhang, Fan
Valdez, Hernan
Clibborn, Claire
Yin, Natalie
Clinical trials referenced in this document:
Documents that mention this clinical trial
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
https://doi.org/10.1007/s40257-022-00738-4
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
https://doi.org/10.1007/s13555-022-00694-1
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Funding for this research was provided by:
Pfizer
Article History
Received: 17 November 2021
Accepted: 14 February 2022
First Online: 17 March 2022